Stock Scorer

BioNTech SE (BNTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in EUR. Every figure as a table ›

Revenue Annual

0 7B 14B 21B FY21: 19B FY22: 17.3B FY23: 3.8B FY24: 2.8B FY25: 2.9B FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 40M 80M 120M FY17: 52.3M FY18: 113.9M FY19: 91.2M FY17 FY18 FY19

Operating Income Annual

-6B 0 6B 12B 18B FY21: 15.3B FY22: 12.6B FY23: 690.4M FY24: -1.3B FY25: -1.4B FY21 FY22 FY23 FY24 FY25

Net Income Annual

-3.5B 0 3.5B 7B 10.5B FY21: 10.3B FY22: 9.4B FY23: 930.3M FY24: -665.3M FY25: -1.1B FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 1.5B 3B 4.5B FY21: 2.9B FY22: 3B FY23: 599.8M FY24: 541.3M FY25: 641.8M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

0 5B 10B 15B FY21: 889.7M FY22: 13.6B FY23: 5.4B FY24: 207.7M FY25: 456M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-5B 0 5B 10B 15B FY21: 762.2M FY22: 13.2B FY23: 5.1B FY24: -78.8M FY25: 280.9M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 90M 180M 270M FY21: 259.7M FY22: 249.8M FY23: 242.7M FY24: 240.4M FY25: 241.7M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS Annual

-15.00 0.00 15.00 30.00 45.00 FY21: 39.63 FY22: 37.77 FY23: 3.83 FY24: -2.77 FY25: -4.70 FY21 FY22 FY23 FY24 FY25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.